Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.…
Talphera, Inc. Q3 2026 Earnings Call Summary
Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Talphera (NASDAQ: TLPH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 0.7852 USD on 20 November 2026, down 32.3% over 52 weeks. Its 52-week range is 0.6900 USD to 1.570 USD: the price is 50.0% below the high and 13.8% above the low.
Its market capitalisation is 40.80M USD.
Talphera reports return on equity of -83.9%.
It holds more cash than debt, a net cash position of 10.58M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 3.125 USD is 298.0% above the current price. The next earnings report is expected on 22 March 2027.